Activity of MMP-2 and MMP-9 in sera of breast cancer patients

Pathology Research and Practice

Volumn 206, Issue 4, 2010, Pages 241-247

  Stankovic, Sandra ^a   Konjevic, Gordana ^a,b   Gopcevic, Kristina ^b   Jovic, Viktor ^a   Inic, Momcilo ^a   Jurisic, Vladimir ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Breast cancer; Clinicopathological markers; MMP 2; MMP 9; Serum

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; HORMONE RECEPTOR; STEROID RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR VOLUME; ZYMOGRAPHY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME PRECURSORS; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM STAGING; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77950857510     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2009.12.003     Document Type: Article

References (30)

1. Mansour E.G., Ravdin P.M., Dressler L. Prognostic factors in early breast carcinoma. Cancer 1994, 74:381-400.
2. McCawely L.J., Matrisian L.M. Matrix metalloproteinases: multifunctional contributors to tumour progression. Mol. Med. Today 2000, 6:149-156.
3. Foda H.D., Zucker S. Matrix metalloproteinase in cancer invasion, metastasis and angiogenesis. Drug Discovery Today 2001, 6:478-482.
4. Ries C., Petrides P.E. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol. Chem. Hoppe Seyler 1995, 376:345-355.
5. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5:2145-2154.
6. Hofmann U.B., Houben R., Brocker E.B., Becker J.C. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005, 87:307-314.
7. Mignatti P., Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 1993, 73:161-195.
8. Pucci-Minafra I., et al. Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono- and two-dimensional electrophoresis. Matrix Biol. 2001, 20:419-427.
9. Ranuncolo S.M., Armanasco E., Cresta C., Bal De Kier Joffe E., Puricelli L. Plasma MMP-9 (92kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int. J. Cancer 2003, 106:745-751.
10. Decock J., et al. Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clin. Exp. Metastasis 2005, 22:495-502.
11. Konecny G., et al. HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin. Cancer Res. 2001, 7:2448-2457.
12. Pellikainen J.M., et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin. Cancer Res. 2004, 10:7621-7628.
13. Tan M., Yao J., Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997, 57:1199-1205.
14. Somiari S.B., et al. Circulating MMP2 and MMP9 in breast cancer -potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int. J. Cancer 2006, 119:1403-1411.
15. Stetler-Stevenson W.G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990, 9:289-303.
16. Kleiner D.E., Stetler-Stevenson W.G. Quantative zymography detection of picogram quantities of gelatinases. Anal. Biochem. 1994, 218:325-329.
17. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
18. Cikota B.M., Brankovic-Magic M.V., Jovic V.S., Radulovic S.S., Magic Z.M. Analysis of T-cell clonality pattern in tumor samples of breast cancer patients. Int. J. Biol. Markers 2005, 20:177-183.
19. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J. Clin. Oncol. 2001, 19:3817-3827.
20. Zucker S., et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann. N Y Acad. Sci. 1999, 878:212-227.
21. La Rocca G., Pucci-Minafra I., Marrazzo A., Taormina P., Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J. Cancer 2004, 90:1414-1421.
22. Li H.C., et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res. Treat. 2004, 88:75-85.
23. Thompson E.W., Reich R., Shima T.B. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 1988, 48:6764-6768.
24. Van den Brule F.A., Engel J., Stetler-Stevenson W.G. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells. Int. J. Cancer 1992, 52:653-657.
25. Crowe J.P., Hubay C.A., Pearson O.H. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res. Treat. 1982, 2:171-176.
26. Hupperets P.S., Volovics L., Schouten L.J. The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer. Am. J. Clin. Oncol. 1997, 20:546-551.
27. Pichon M.F., Broet P., Magdelenat H. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br. J. Cancer 1996, 73:1545-1551.
28. Dickson R.B., Lippman M.E. Growth factors in breast cancer. Endocr. Rev. 1995, 16:559-589.
29. Sahin A. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv. Anat. Pathol. 2000, 7:158-166.
30. Berney C.R., Yang J., Fisher R.J., Russell P.J., Crowe P.J. Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. Oncol. Res. 1998, 10:47-54.